Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: Prospective randomised double-blind study

Hong Kong Medical Journal

Volumn 6, Issue 4, 2000, Pages 368-374

  Ng, E H Y ^a   Yeung, W S B ^a   Ho, P C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Fertilization in vitro; FSH administration dosage; Ovulation induction; Pregnancy rate; Recombinant proteins administration dosage

Indexed keywords

RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FERTILIZATION IN VITRO; HONG KONG; HUMAN; HUMAN CELL; OOCYTE; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PATIENT SELECTION; PREGNANCY RATE; RANDOMIZED CONTROLLED TRIAL;

ADULT; BODY MASS INDEX; CHINA; DOUBLE-BLIND METHOD; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; HUMANS; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RECOMBINANT PROTEINS;

EID: 0034475161     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Clinical outcome of a pilot efficacy study on recombinant human follicle-stimulating hormone (Org 32489) combined with various gonadotrophin-releasing hormone agonist regimens
2. Efficacy and safety of recombinant follicle stimulating hormone (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilization: A prospective, randomized, assessor-blind multicentre trial
3. A prospective, randomized, assessor-blind, multicentre study comparing recombinant follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization
4. The use of a 100 IU starting dose of recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization
5. A prospective, randomized, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon) in women undergoing ovarian stimulation
6. High serum oestradiol levels in fresh IVF cycles do not impair implantation and pregnancy rates in subsequent FET cycles
7. An 18-month survey of infertility treatment by in vitro fertilization, gamete and zygote intrafallopian transfer, and replacement of frozen-thawed embryos
8. Reduced in vitro fertilization of human oocytes from patients with raised basal luteinising hormone levels during the follicular phase
9. Influence of serum luteinising hormone concentrations on ovulation, conception and early pregnancy loss in polycystic ovary syndrome
10. Use of recombinant human follicle-stimulating hormone for in vitro fertilization-embryo transfer after severe systemic immunoglobulin E-mediated reaction to urofollitropin
11. Variability in the immunoreactive and bioactive follicle stimulating hormone content of human urinary menopausal goandotrophin preparation
12. Composition of commercial gonadotropin preparations extracted from human post-menopausal urine: Characterization of non-gonadotropin proteins
13. Follicle-stimulating hormone versus human menopausal gonadotrophin for in vitro fertilization cycles: A meta-analysis
14. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction
15. Premature luteinization in in-vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH
16. Revisiting goadotrophin-releasing hormone agonist protocols and management of poor ovarian responses to gonadotrophins
17. Minimal ovarian stimulation for IVF: Appraisal of potential benefits and drawbacks
18. The detection of diminished ovarian reserve in infertile women
19. Measurement of ovarian volume by transvaginal sonography before ovulation induction with human menopausal gonadotrophin for in-vitro fertilization can predict poor response
20. Ovarian volume may predict assisted reproductive outcome better than follicle stimulating hormone concentration on day 3
21. Pretreatment transvaginal ultrasound examination predicts ovarian responsiveness to gonadotrophins in in-vitro fertilization
22. Use of the antral follicle count to predict the outcome of assisted reproductive technologies
23. The significance of the number of antral follicles prior to stimulation in predicting ovarian responses in an in-vitro fertilization programme